Fundamentals and catalytic innovation: The statistical and data management center of the antibacterial resistance leadership group

Clinical Infectious Diseases

Volumn 64, Issue , 2017, Pages S18-S23

  Huvane, Jacqueline ^a   Komarow, Lauren ^b   Hill, Carol ^a   Tran, Thuy Tien T ^b   Pereira, Carol ^a   Rosenkranz, Susan L ^b   Finnemeyer, Matt ^c   Earley, Michelle ^b   Jiang, Hongyu ^b   Wang, Rui ^b,d   Lok, Judith ^b   Evans, Scott R ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibacterial Resistance; Data; Innovation; Statistics

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; EDUCATION; HUMAN; INFORMATION CENTER; INFORMATION PROCESSING; LEADERSHIP; MEDICAL INFORMATION; MONITORING; PRIORITY JOURNAL; STATISTICS; STUDY DESIGN; HEALTH CARE PLANNING; INFORMATION SYSTEM; MEDICAL EDUCATION; ORGANIZATION AND MANAGEMENT; PROCEDURES; RESEARCH; STANDARDS;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; DATA COLLECTION; DRUG RESISTANCE, BACTERIAL; EDUCATION, MEDICAL; HEALTH RESOURCES; HUMANS; INFORMATION MANAGEMENT; RESEARCH;

EID: 85033568199     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw827     Document Type: Article

References (29)

1. Chambers HF, Bartlett JG, Bonomo RA, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis 2014;58:1571-6.
2. Anderson DJ, Jenkins TC, Evans SR, et al. The role of stewardship in antibiotic resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S36-40.
3. Evans SR, Powers J. Evaluating anti-infective drugs in the resistant pathogen setting: can we use external controls? Stat Commun Infect Dis. In press.
4. Evans SR, Follmann D. Comment: fundamentals and innovation in antibiotic trials. Stat Biopharm Res 2015;7:331-6.
5. Evans SR, Harris AD. Methods and issues in studies of CRE. Virulence 2016. doi: 10.1080/21505594.2016.1213473.
6. Stafford KA, Boutin M, Evans SR, Harris AD. Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies. Clin Infect Dis 2014;59:1142-7.
7. Manca C, Hill C, Hujer AM, et al. Leading antibacterial laboratory research by integrating conventional and innovative approaches: the Laboratory Center of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S13-7.
8. Evans SR, Pennello G, Pantoja-Galicia N, et al; Antibacterial Resistance Leadership Group. Benefit-risk evaluation for diagnostics: a framework (BED-FRAME). Clin Infect Dis 2016;63:812-7.
9. Evans SR, Jiang H, Hujer AM, et al. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics (RMDs) to identify susceptibility and resistance to carbapenems against Acinetobacter spp. PRIMERS-III. J Clin Microbiol 2016. doi:10.1128/JCM.01524-16.
10. Evans SR, Tran T T, Hujer A, et al. Choosing ceftazidime/avibactam and ceftolozane/tazobactam as empiric therapies against Pseudomonas aeruginosa (Pa) using rapid molecular diagnostics (RMDs): PRIMERS IV [abstract]. In: IDWeek 2016. New Orleans, LA, 26-30 October 2016.
11. Evans SR, Hujer AM, Jiang H, et al; Antibacterial Resistance Leadership Group. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016;62:181-9.
12. Evans SR, Follmann D. Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit: risk evaluation. Stat Biopharm Res. In press.
13. Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis 2015;61:800-6.
14. Evans SR, Holland T, Doernberg S, et al. Using endpoints to analyze patients rather than patients to analyze endpoints: a pre-trial substudy to develop a global outcome for clinical trials [abstract]. In: Society for Clinical Trials. Montreal, Canada, 2016. Available at: http://www.sctweb.org/public/search/detail. cfm?ID=750B380C-D56B-C7B3-4F1A851008C26872. Accessed 1 November 2016.
15. Evans SR, Li L, Wei LJ. Data monitoring in clinical trials using prediction. Ther Innov Regul Sci 2007;41:733-42.
16. Li L, Evans SR, Uno H, Wei LJ. Predicted interval plots (PIPS): a graphical tool for data monitoring of clinical trials. Stat Biopharm Res 2009;1:348-55.
17. Uno H, Wittes J, Fu H, et al. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies. Ann Intern Med 2015;163:127-34.
18. Ochiai T, Hamasaki T, Evans SR, Asakura K, Ohno Y. Group-sequential threearm noninferiority clinical trial designs. J Biopharm Stat 2015. doi:10.1080/1054 3406.2016.1148710.
19. Evans SR. When and how can endpoints be changed after initiation of a randomized clinical trial? PLoS Clin Trials 2007;2:e18.
20. Ando Y, Hamasaki T, Evans SR, et al. Sample size considerations in clinical trials when comparing two interventions using multiple co-primary binary relative risk contrasts. Stat Biopharm Res 2015;7:81-94.
21. Hamasaki T, Asakura K, Evans SR, Sugimoto T, Sozu T. Group-sequential strategies in clinical trials with multiple co-primary outcomes. Stat Biopharm Res 2015;7:36-54.
22. Asakura K, Hamasaki T, Sugimoto T, Hayashi K, Evans SR, Sozu T. Sample size determination in group-sequential clinical trials with two co-primary endpoints. Stat Med 2014;33:2897-913.
23. Sozu T, Sugimoto T, Hamasaki T. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables. Biom J 2012;54:716-29.
24. Hamasaki T, Asakura K, Evans SR, Ochiai T. Group-sequential clinical trials with multiple co-objectives. In: Kunitomo N, Takemura A, ed. SpringerBriefs in Statistics. New York: Springer, 2016.
25. Asakura K, Hamasaki T, Evans SR. Interim evaluation of efficacy or futility in clinical trials with two co-primary endpoints. In: Hamasaki T, et al. Group-Sequential Clinical Trials With Multiple Co-Objectives. SpringerBriefs in Statistics. New York: Springer, 2016.
26. Asakura K, Hamasaki T, Evans SR, Sugimoto T, Sozu T. Group-sequential designs when considering two binary outcomes as co-primary endpoints. In: Chen Z, et al, ed. Applied Statistics in Biomedicine and Clinical Trial Designs. New York: Springer, 2014.
27. Tsalik EL, Petzold E, Kreiswirth BN, et al. Advancing diagnostics to address antibacterial resistance: the Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Clin Infect Dis 2017;64(Suppl 1):S41-7.
28. Pennello G, Pantoja-Galicia N, Evans S. Comparing diagnostic tests on benefit-risk. J Biopharm Stat 2016;26:1083-97.
29. Molina J, Cisneros JM. Editorial commentary: a chance to change the paradigm of outcome assessment of antimicrobial stewardship programs. Clin Infect Dis 2015;61:807-8.